1by6: Difference between revisions

← Older edit

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
 ==Peptide of human apolipoprotein C-II==
-<StructureSection load='1by6' size='340' side='right' caption='[[1by6]], [[NMR_Ensembles_of_Models | 19 NMR models]]' scene=''>
+<StructureSection load='1by6' size='340' side='right'caption='[[1by6]]' scene=''>
 == Structural highlights ==
-<table><tr><td colspan='2'>[[1by6]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1BY6 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1BY6 FirstGlance]. <br>
+<table><tr><td colspan='2'>[[1by6]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1BY6 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=1BY6 FirstGlance]. <br>
-</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1by6 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1by6 OCA], [http://pdbe.org/1by6 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=1by6 RCSB], [http://www.ebi.ac.uk/pdbsum/1by6 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=1by6 ProSAT]</span></td></tr>
+</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Solution NMR</td></tr>
+<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=1by6 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1by6 OCA], [https://pdbe.org/1by6 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=1by6 RCSB], [https://www.ebi.ac.uk/pdbsum/1by6 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=1by6 ProSAT]</span></td></tr>
 </table>
 == Disease ==
-[[http://www.uniprot.org/uniprot/APOC2_HUMAN APOC2_HUMAN]] Defects in APOC2 are the cause of hyperlipoproteinemia type 1B (HLPP1B) [MIM:[http://omim.org/entry/207750 207750]]. It is an autosomal recessive trait characterized by hypertriglyceridemia, xanthomas, and increased risk of pancreatitis and early atherosclerosis.<ref>PMID:8323539</ref>
+[https://www.uniprot.org/uniprot/APOC2_HUMAN APOC2_HUMAN] Defects in APOC2 are the cause of hyperlipoproteinemia type 1B (HLPP1B) [MIM:[https://omim.org/entry/207750 207750]. It is an autosomal recessive trait characterized by hypertriglyceridemia, xanthomas, and increased risk of pancreatitis and early atherosclerosis.<ref>PMID:8323539</ref>
 == Function ==
-[[http://www.uniprot.org/uniprot/APOC2_HUMAN APOC2_HUMAN]] Component of the very low density lipoprotein (VLDL) fraction in plasma, and is an activator of several triacylglycerol lipases. The association of APOC2 with plasma chylomicrons, VLDL, and HDL is reversible, a function of the secretion and catabolism of triglyceride-rich lipoproteins, and changes rapidly.
+[https://www.uniprot.org/uniprot/APOC2_HUMAN APOC2_HUMAN] Component of the very low density lipoprotein (VLDL) fraction in plasma, and is an activator of several triacylglycerol lipases. The association of APOC2 with plasma chylomicrons, VLDL, and HDL is reversible, a function of the secretion and catabolism of triglyceride-rich lipoproteins, and changes rapidly.
 == Evolutionary Conservation ==
 [[Image:Consurf_key_small.gif|200px|right]]
@@ Line 20: / Line 21: @@
 </jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=1by6 ConSurf].
 <div style="clear:both"></div>
-<div style="background-color:#fffaf0;">
-== Publication Abstract from PubMed ==
-We have studied the three-dimensional structure of a biologically active peptide of apolipoprotein C-II (apoC-II) in the presence of lipid mimetics by CD and NMR spectroscopy. This peptide, corresponding to residues 44-79 of apoC-II, has been shown to reverse the symptoms of genetic apoC-II deficiency in a human subject. A comparison of alpha-proton secondary shifts and CD spectroscopic data indicates that the structure of apoC-II(44-79) is similar in the presence of dodecylphosphocholine and sodium dodecyl sulfate. The three-dimensional structure of apoC-II(44-79) in the presence of sodium dodecyl sulfate, determined by relaxation matrix calculations, contains two amphipathic helical domains formed by residues 50-58 and 67-75, separated by a non-helical linker centered at Tyr63. The C-terminal helix is terminated by a loop formed by residues 76-79. The C-terminal helix is better defined and has a larger hydrophobic face than the N-terminal helix, which leads us to propose that the C-terminal helix together with the non-helical Ile66 constitute the primary lipid binding domain of apoC-II(44-79). Based on our structure we suggest a new mechanism of lipoprotein lipase activation in which both helices of apoC-II(44-79) remain lipid bound, while the seven-residue interhelical linker extends away from the lipid surface in order to project Tyr63 into the apoC-II binding site of lipoprotein lipase.
-Structure of a biologically active fragment of human serum apolipoprotein C-II in the presence of sodium dodecyl sulfate and dodecylphosphocholine.,Storjohann R, Rozek A, Sparrow JT, Cushley RJ Biochim Biophys Acta. 2000 Jul 19;1486(2-3):253-64. PMID:10903476<ref>PMID:10903476</ref>
-From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-</div>
-<div class="pdbe-citations 1by6" style="background-color:#fffaf0;"></div>
 == References ==
 <references/>
 __TOC__
 </StructureSection>
-[[Category: Cushley, R J]]
+[[Category: Homo sapiens]]
-[[Category: Rozek, A]]
+[[Category: Large Structures]]
-[[Category: Sparrow, J T]]
+[[Category: Cushley RJ]]
-[[Category: Storjohann, R]]
+[[Category: Rozek A]]
-[[Category: Amphipathic helix]]
+[[Category: Sparrow JT]]
-[[Category: Apolipoprotein]]
+[[Category: Storjohann R]]
-[[Category: Lipid association]]
-[[Category: Lpl activation]]
-[[Category: Signaling protein]]